Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Trials

Set Alert for Clinical Trials

Sensyne Health CEO Drayson Says IPO Will See AI Group To Profitability

Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.

Artificial Intelligence Business Strategies

Gemphire Reels From Two R&D Blows

A series of setbacks for gemcabene has left the Livonia, MI-based company reeling, but management remains committed to its lead product.

Clinical Trials Research & Development

Evotec Sets Empire Building Sights On Infectious Disease Space

As others shun anti-infectives, Evotec is consolidating its position. Through an alliance with Sanofi it is evaluating new anti-infectives in three areas, and expects soon to advance its first candidate therapeutic into the clinic.


Infectious Diseases Clinical Trials

RedHill's Antibiotic Approach For Crohn's Shows Promise, Caveats Remain

Top-line data for a Phase III trial of RedHill's antibiotic combination for use in Crohn's disease show the study has hit its primary endpoint, but there is still some way to go before filings can be made for the novel approach.

Clinical Trials Research & Development

Lundbeck Breaks Into MAb Development, Adds To Suite Of Parkinson's Candidates

Denmark's mid-sized biopharma, Lundbeck, has taken another potential Parkinson's disease therapeutic into early clinical studies, the third this year, and this time it's a monoclonal antibody, not a small molecule.


Neurology Research & Development

Ironwood Pulls Plug On Struggling Gout Drug Zurampic

Due to poor sales, the drug, which AstraZeneca picked up through its $1.26bn acquisition of Ardea, is now being terminated in the US. Ironwood, already in the process of splitting up, is going to focus on its core gastrointestinal franchise.

Sales & Earnings Clinical Trials

Onward Ho! Glenmark Strikes First Onco Asset Deal With China’s Harbour BioMed

Glenmark has sealed a licensing deal for its early stage immuno-oncology asset with China’s Harbour BioMed, opening up new possibilities around collaborations between the two Asian nations. The Indian firm appears upbeat about the prospects of building further on this new linkage.

Deals Research & Development

PCSK9 Pick-Me-Up: New Cholesterol Guidelines May Mean Lower LDL Targets

Sales of PCSK9 inhibitors have been improving, though are still low, and inclusion of lower LDL-C targets in practice guidelines coming this November would be a boost.

Clinical Trials Research & Development

Tazemetostat Setbacks Hit Epizyme

As drug fails in DLBCL, firm focuses on lifting partial clinical hold on other trials. A first filing in a rare sarcoma has also been pushed back.

Clinical Trials Research & Development
See All